{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:48:45Z","timestamp":1791611325108,"version":"4.3.4"},"reference-count":15,"publisher":"Japanese Urological Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. j. urol"],"published-print":{"date-parts":[[2026,1,20]]},"DOI":"10.5980\/jpnjurol.117.1","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:13:20Z","timestamp":1791497600000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["CORRELATION BETWEEN RELATIVE DOSE INTENSITY AND TREATMENT OUTCOMES OF ENFORTUMAB VEDOTIN IN PATIENTS WITH LOCALLY ADVANCED\/METASTATIC UROTHELIAL CARCINOMA","Enfortumab vedotin\u5358\u5264\u6cbb\u7642\u306b\u304a\u3051\u308bRelative dose intensity\u3068\u6cbb\u7642\u30a2\u30a6\u30c8\u30ab\u30e0\u306e\u691c\u8a0e"],"prefix":"10.5980","volume":"117","author":[{"given":"Yuma","family":"Sakura","sequence":"first","affiliation":[{"name":"Division of Urology, Shizuoka Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Division of Urology, Shizuoka Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Urology, Shizuoka Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Shinsaka","sequence":"additional","affiliation":[{"name":"Division of Urology, Shizuoka Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Urology, Shizuoka Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Matsuzaki","sequence":"additional","affiliation":[{"name":"Division of Urology, Shizuoka Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Niwakawa","sequence":"additional","affiliation":[{"name":"Division of Urology, Shizuoka Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4001","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M and Petrylak DP: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med, 384, 1125-1135, 2021.","DOI":"10.1056\/NEJMoa2035807"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kanda Y: Investigation of the freely available easy-to-use software  'EZR' for medical statistics. Bone Marrow Transplant, 48, 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, G\u00fcm\u00fc\u015f M, Mar N, Loriot Y, Fl\u00e9chon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B and van der Heijden MS: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med, 390, 875-888, 2024.","DOI":"10.1056\/NEJMoa2312117"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A and Petrylak DP: Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1\/Programmed Death Ligand 1 Therapy. J Clin Oncol, 37, 2592-2600, 2019.","DOI":"10.1200\/JCO.19.01140"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Mamtani R, Tsingas K, Parikh RB, Elsouda D, Mucha L, Fuldeore R and Hubbard RA: Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer. Urol. Oncol, 42, 177.e1-e4, 2024.","DOI":"10.1016\/j.urolonc.2024.03.001"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N and Fujimoto K: Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort. Jpn J Clin Oncol, 54, 329-338, 2024.","DOI":"10.1093\/jjco\/hyad170"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Mamtani R, Wu C, Matsangou M, Campbell M and Petrylak DP: EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol, 34, 1047-1054, 2023.","DOI":"10.1016\/j.annonc.2023.08.016"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Endo Y, Akatsuka J, Takeda H, Hasegawa H, Yanagi M, Toyama Y, Mikami H, Shibasaki M, Kimura G and Kondo Y: Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions. Curr Oncol, 31, 759-768, 2024.","DOI":"10.3390\/curroncol31020056"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Minato A, Furubayashi N, Tomoda T, Masaoka H, Song Y, Hori Y, Kiyoshima K, Negishi T, Kuroiwa K, Seki N, Tomisaki I, Nakamura M, Harada K and Fujimoto N: Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy. Anticancer Res, 44, 3419-3426, 2024.","DOI":"10.21873\/anticanres.17162"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, Saruta M, Takahara K, Fujita K, Minami T, Adachi T, Hirasawa Y, Hashimoto T, Ohno Y, Uemura H, Shiroki R, Azuma H and Kimura T: Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study. Int J Urol, 31, 342-347, 2024.","DOI":"10.1111\/iju.15368"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Hayakawa N, Kikuchi E, Kaneko G, Yamashita R, Ikarashi D, Endo Y, Usui K, Obara W, Oyama M and Kondo Y: Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study. Jpn J Clin Oncol, 54, 1194-1200, 2024.","DOI":"10.1093\/jjco\/hyae082"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Vlachou E, Matoso A, McConkey D, Jing Y, Johnson BA, Hahn NM and Hoffman-Censits J: Enfortumab Vedotin-related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature. Eur Urol Open Sci, 49, 100-103, 2023.","DOI":"10.1016\/j.euros.2023.01.002"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Furubayashi N, Negishi T, Mochida M, Kijima A, Katsuki H and Nakamura M: Impact of Relative Dose Intensity of Enfortumab Vedotin for Advanced Urothelial Carcinoma. In Vivo, 39, 411-418, 2025.","DOI":"10.21873\/invivo.13843"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Miyake M, Nishimura N, Iemura Y, Yoshikawa M, Torimoto K, Tomioka A, Sakamoto K, Matsumura Y, Naoi M, Ichii D, Inoue K, Narita K, Oyama N, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Tanaka N and Fujimoto K; Nara Urological Research and Treatment Group: Impact of initial relative dose intensity on tumor response and survival outcomes in enfortumab vedotin monotherapy for previously treated advanced urothelial carcinoma: A real-world analysis from a multicenter study. Clin Genitourin Cancer, Articles in press, 2025.","DOI":"10.1016\/j.clgc.2025.102326"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Takahashi S, Uemura M, Kimura T, Kawasaki Y, Takamoto A, Yamaguchi A, Melhem-Bertrandt A, Gartner EM, Inoue T, Akazawa R, Kadokura T and Tanikawa T: A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma. Invest New Drugs, 38, 1056-1066, 2020.","DOI":"10.1007\/s10637-019-00844-x"}],"container-title":["The Japanese Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/117\/1\/117_1\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:55:19Z","timestamp":1791608119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/117\/1\/117_1\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5980\/jpnjurol.117.1","relation":{},"ISSN":["0021-5287","1884-7110"],"issn-type":[{"value":"0021-5287","type":"print"},{"value":"1884-7110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]}}}